Lenvatinib treatment for thyroid cancer in COVID era: safety in a patient with lung metastases and SARS-CoV-2 infection

During the coronavirus disease 2019 (COVID-19) pandemic, clinicians are required to manage patient care for pre-existing conditions. Currently, there are no clear indications regarding the management of lenvatinib-treated patients for radioiodine-refractory thyroid cancer and severe acute respirator...

Descripción completa

Detalles Bibliográficos
Autores principales: Locantore, Pietro, Del Gatto, Valeria, Corsello, Andrea, Pontecorvi, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517101/
https://www.ncbi.nlm.nih.gov/pubmed/34183494
http://dx.doi.org/10.1097/CAD.0000000000001097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517101/
https://www.ncbi.nlm.nih.gov/pubmed/34183494
http://dx.doi.org/10.1097/CAD.0000000000001097

Ejemplares similares